Court Finds United Therapeutics’ Interference with Launch of Generic Treprostinil Injection Caused Losses of More Than $137 Million
September 16, 2024 09:41 ET
|
Liquidia Corporation
MORRISVILLE, N.C., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia), a biopharmaceutical company developing innovative therapies for patients with rare...
Liquidia Corporation Announces Raise of $67.5 Million from New Common Stock Financings and $32.5 Million Advance from HealthCare Royalty Under Current Financing Agreement
September 11, 2024 08:26 ET
|
Liquidia Corporation
Liquidia Corporation announces raise of $67.5M.
Liquidia to Present at Upcoming Investor Conferences
August 28, 2024 08:00 ET
|
Liquidia Corporation
Liquidia Corporation (LQDA) announced today that the company will present at two investor conferences this September.
Liquidia Files Litigation to Challenge Regulatory Exclusivity Blocking Access to YUTREPIA™ (treprostinil) inhalation powder for Patients Suffering with PAH and PH-ILD
August 22, 2024 06:00 ET
|
Liquidia Corporation
Liquidia has filed litigation that challenges the recent decision by the FDA to grant 3-year new clinical investigation exclusivity to Tyvaso DPI.
U.S. FDA Grants Tentative Approval of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
August 19, 2024 06:00 ET
|
Liquidia Corporation
The FDA has granted tentative approval of YUTREPIA™ (treprostinil) inhalation powder to treat adults with PAH and PH-ILD.
Liquidia Announces Poster Presentations at the PHA 2024 International PH Conference and Scientific Sessions
August 16, 2024 06:30 ET
|
Liquidia Corporation
Liquidia Corporation (NASDAQ: LQDA) will present nine encore thematic posters at the 2024 Pulmonary Hypertension Association (PHA) International Conference
Liquidia Corporation Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 07, 2024 06:30 ET
|
Liquidia Corporation
Liquidia Corporation (NASDAQ: LQDA) today reported financial results for the second quarter ended June 30, 2024.
Liquidia Corporation to Report Second Quarter 2024 Financial Results on August 7, 2024
July 31, 2024 08:00 ET
|
Liquidia Corporation
Liquidia Corporation to report second quarter 2024 financial results on
August 7, 2024.
Liquidia Announces Poster Presentations at the 7th World Symposia on Pulmonary Hypertension (WSPH)
June 18, 2024 08:42 ET
|
Liquidia Corporation
Liquidia to feature two live posters sessions and five encore presentations covering its investigational products, YUTREPIA™ (treprostinil) inhalation powder and L606 (liposomal treprostinil)...
District Court Issues Favorable Ruling and Denies United Therapeutics’ Request to Block YUTREPIA™ Launch
June 03, 2024 07:00 ET
|
Liquidia Corporation
Judge Andrews denied the motion for preliminary injunction filed by United Therapeutics that sought to block the launch of Liquidia’s YUTREPIA™.